Ginkgo Bioworks Holdings, Inc.

As of October 10, 2025, Ginkgo Bioworks Holdings, Inc. has a mildly bullish technical outlook, supported by a bullish weekly MACD and moving averages, despite a recent 11.5% decline, while outperforming the S&P 500 with a 79.54% return over the past year.

As of October 10, 2025, Ginkgo Bioworks Holdings, Inc. has a mildly bullish technical trend, supported by bullish daily moving averages and a strong performance of 88.3% over the past year, despite mixed signals from the MACD and KST indicators.

As of October 10, 2025, Ginkgo Bioworks Holdings, Inc. has a mildly bullish technical trend, supported by positive moving averages and a strong performance relative to the S&P 500, despite some caution from the KST indicators.

As of October 3, 2025, Ginkgo Bioworks Holdings, Inc. shows a bullish technical trend driven by daily moving averages and the weekly MACD, despite mild bearishness in the KST and a sideways monthly Bollinger Bands.

As of October 3, 2025, Ginkgo Bioworks Holdings, Inc. has a bullish technical trend, supported by positive indicators, and has significantly outperformed the S&P 500 with a 1-year return of 98.77% compared to 17.82%.

As of September 2, 2025, Ginkgo Bioworks Holdings, Inc. has a mildly bullish technical trend, with mixed signals from various indicators, outperforming the S&P 500 over the past week and year.

As of August 16, 2021, Ginkgo Bioworks Holdings, Inc. is considered a risky investment due to its negative P/E ratio, significant losses reflected in a -60.42% ROE, and poor valuation metrics compared to peers, despite a strong 1-year stock return of 54.12%.

As of August 16, 2021, Ginkgo Bioworks Holdings, Inc. is considered overvalued with a valuation grade of "risky," reflected in its low price-to-book ratio of 0.69, an EV to EBITDA of 0.25, a negative ROE of -60.42%, and a poor one-year stock return of -49.75% compared to the S&P 500's gain of 10.26%.

As of May 1, 2025, the trend is mildly bearish due to daily moving averages indicating a bearish trend, despite mixed signals from weekly and monthly indicators.

Ginkgo Bioworks Holdings, Inc. is a small-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $48 million and a net loss of $91 million as of March 2025. Key metrics include a market cap of $500.45 million, a P/E ratio of NA, and a debt-to-equity ratio of -0.81.

As of Jun 18, Ginkgo Bioworks Holdings, Inc. has a market capitalization of 500.45 million, with net sales of 237.43 million and a net profit of -472.07 million over the latest four quarters. The company reported shareholder's funds of 716.06 million and total assets of 1,377.45 million as of Dec 24.